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Nonsteroidal anti-inflammatory drugs (NSAIDs) are frequently used to reduce pain and inflammation. However, their effect on
bone metabolisms is not well known, and results in the literature are contradictory. The present study focusses on the effect
of dexketoprofen, ketorolac, metamizole, and acetylsalicylic acid, at therapeutic doses, on different biochemical and phenotypic
pathways in human osteoblast-like cells. Osteoblasts (MG-63 cell line) were incubated in culture medium with 1–10𝜇M of
dexketoprofen, ketorolac, metamizole, and acetylsalicylic acid. Flow cytometry was used to study antigenic profile and phagocytic
activity.The osteoblastic differentiation was evaluated bymineralization and synthesis of collagen fibers bymicroscopy and alkaline
phosphatase activity (ALP) by spectrophotometric assay. Short-term treatment with therapeutic doses of NSAIDs modulated
differentiation, antigenic profile, and phagocyte activity of osteoblast-like cells. The treatment reduced ALP synthesis and matrix
mineralization. However, nonsignificant differences were observed on collagen syntheses after treatments.The percentage of CD54
expression was increased with all treatments. CD80, CD86, and HLA-DR showed a decreased expression, which depended on
NSAID and the dose applied. The treatments also decreased phagocyte activity in this cellular population. The results of this
paper provide evidences that NSAIDs inhibit the osteoblast differentiation process thus reducing their ability to produce new bone
mineralized extracellular matrix.
1. Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs) are com-
monly prescribed by their therapeutic indications (anti-
inflammatory, analgesic, and antipyretic) [1, 2]. The clin-
ical effectiveness of NSAIDs is based on the inhibition
of cyclooxygenase (COX) activity, leading to diminished
prostaglandin production [1, 3, 4]. They are administered
postoperatively and posttraumatically to achieve analgesia
and to reduce inflammation especially in the bony tissue.
However, over the last two decades, several studies have
suggested that NSAIDs interfere with bone healing by sup-
pressing its growth and remodeling. The biochemical and
cellular pathways affected by this inhibitory action are not
fully understood, and many authors have attributed this
effect to an impaired osteoblasts proliferative capacity [5–9].
However, other authors have ascertained that NSAIDs, like
aspirin or ibuprofen, did not affect bone cells proliferation
capacity at therapeutic doses [10, 11].
Studies have also been focusing on the effect of NSAIDs
on osteoblast differentiation. Arpornmaeklong et al. (2008)
[12] found that indomethacin and celecoxib inhibit cell
growth but have a less clear effect on cell differentiation as
determined by alkaline phosphatase and osteocalcin synthe-
sis. The inhibitory role of NSAID on osteoblast proliferation
and the increase of cell apoptosis through the cyclooxygenase
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2 (COX-2) activity has also suggested a potential therapeutic
role of these drugs in cancer treatment [13].
However, the process of bone formation and bone remod-
eling goes beyond osteoblast proliferation and differentiation
and these processes are finely regulated by both endogenous
and exogenous stimuli. Indeed, osteoblasts differentiation of
which is regulated by a large number of paracrine, autocrine,
and endocrine factors such us growth factors, hormones
and cytokines [14, 15] and it is reported that the activity
of these cells is regulated by mechanical stimuli. In turn,
osteoblasts participate in bone metabolism also regulating
osteoclast activity and recent investigations have highlighted
their role in the immune response. This immunological
function has been shown to include phagocytic activity,
T lymphocyte stimulation, and cytokine synthesis [16–20].
Histological studies have highlighted the ability of osteoblast
to present antigens [21], while primary cultures and human
osteosarcoma cell line MG-63 studies have clearly indicated
the phagocytic capacity of osteoblasts against foreign bodies
of different size and chemical source [19, 22–24].
Thepresent study analyses the short-term effect of clinical
doses of various types of NSAIDs, dexketoprofen, ketorolac,
metamizole and acetylsalicylic acid on cell line osteoblasts,
MG-63. Short-term culture conditions were chosen to pin-
point the early biochemical pathways triggered by the drugs
that lead to impaired bone metabolism and to determine
which phenotype was mainly affected by their presence.
2. Material and Methods
2.1. Cell Culture. The human MG-63 osteosarcoma cell line
was purchased from American Type Cultures Collection
(ATCC, Manassas, VA) and maintained as described by De
Luna-Bertos et al. (2012) [11] in Dulbecco’s Modified Eagle
Medium (DMEM; Invitrogen Gibco Cell Culture Products,
Carlsbad, CA) with 100 IU/mL penicillin (Lab Roger SA,
Barcelona, Spain), 50𝜇g/mL gentamicin (BraumMedical SA,
Jae´n, Spain), 2.5𝜇g/mL amphotericin B (Sigma, St Louis,MO,
USA), 1% L-glutamine (u/v) (Sigma, St Louis, MO, USA), 2%
HEPES (Sigma, St Louis, MO, USA), and supplemented with
10% (v/v) Fetal Bovine Serum (FBS) (Gibco, Paisley, UK).
Cultures were kept at 37∘C in a humidified atmosphere of 95%
air and 5% CO
2
. Cells were detached from culture flask with
a solution of 0.05% trypsin (Sigma, St Louis, MO, USA), and
0.02% ethylenediaminetetraacetic acid (w/v) (EDTA) (Sigma,
St Louis, MO, USA) and then washed and suspended in
complete culture medium with 10% FBS.
The cells were treated with different drugs, metamizole,
dexketoprofen, ketorolac, or acetylsalicylic acid, purchased
from Sigma (Sigma, St Louis, MO, USA), at a dose of 1 or
10 𝜇M or without NSAID as control, during different period
of time depending on the assay.
2.2. Antigenic Phenotype by Flow Cytometry. Osteoblasts
(MG-63 cell line) were previously treated with 1 and 10 𝜇M
of dexketoprofen, ketorolac, metamizole, and acetylsalicylic
acid for 24 h at 37∘C. Cells were then detached from the
cultured flask by treatment with 0.4% (w/v) EDTA solution,
washed, and suspended in Phosphate-Buffered Saline (PBS)
at 2 × 104 cells/mL. Cells were labeled by direct staining with
the monoclonal antibodies (MAbs) listed in Table 1. Aliquots
of 100𝜇L of cell suspension were incubated with 10 𝜇L of
the appropriate MAb for 30 min at 4∘C in the dark. Cells
were washed, suspended in 1mL of PBS, and immediately
analyzed in a flow cytometer with diodo laser (FASC Canton
II, SE Becton Dickinson, Palo Alto, California, USA) at
a wavelength of 488 nm to determine the percentage of
fluorescent cells. Untreated cells were used as control group.
The percentage of antibody-positive cells was calculated from
counts of 2000–3000 cells. At least three experiments were
run for each antigen in all cultures.
2.3. Phagocytic Activity of MG-63 Lines. Phagocytic activity
was studied by flow cytometry. Cultured humanMG-63 cells
were treated with 1 and 10 𝜇M of dexketoprofen, ketorolac,
metamizole, and acetylsalicylic acid. Untreated cells were
used as control group. Cells were detached from the culture
flask by treatment with a solution of 0.05% (w/v) trypsin and
0.02% (w/v) EDTA, washed, and then suspended in complete
culture medium with 10% (v/v) FBS at 2 × 104 cells/mL.
Cells were labeled by direct staining with labeled latex beads.
One hundred microliters of cell suspension were incubated
with 200𝜇L carboxylated FICT-labeled latex beads of 2𝜇m
of diameter (Sigma Adrich, St Louis, USA) for 30min at 37∘C
in darkness. Cells were washed, suspended in 1mL of PBS,
and immediately analyzed in a flow cytometer (FASC Canton
II, SE Becton Dickinson, Palo Alto, California, USA). Results
were expressed as percentage of cells positive for phagocytosis
and mean channel fluorescence, which correlates with the
number of phagocytosed particles.
2.4. Cell Differentiation Assay. The effect on osteoblast-
like cells differentiation was assessed by the evaluation of
collagen, ALP levels, and the number of calcium deposits
(matrix mineralization) produced by MG-63 cells cultured
in nonosteogenic and osteogenic mediums and treated with
the different NSAIDs. Cells were seeded in an appropriate
cells number in a 6-well plate or 24-well plates, depending
on assay (Falcon, Becton Dickinson Labware) and cultured
in both mediums at 37∘C in a humidified atmosphere of 95%
air and 5% CO
2
.
Osteogenic medium which consists of complete medium
was supplemented with 5mM 𝛽-glycerophosphate and
0.05mM ascorbic acid.
2.4.1. Collagen Synthesis. Cells at 1 × 104 cells/mL per well
into 24-well plates in nonosteogenic and osteogenicmediums
were cultured at different concentrations of NSAIDs. After
24 h of incubation, cells were fixed with 3.7% (w/v) formalin,
and later 500𝜇L of picrosirius red stain (Sirius red F3BA)
were added. After incubation for 1 hour at room temperature,
wells were washed with distiller water three times. Finally,
the samples were analyzed under light microscope (Inverted
NIKON Elipse TE2000U).
Also the cellular morphology was studied by scanning
electron microscopy (SEM), with the aim of analyzing the
fibrin of collagen, after seven days of incubation at different
concentration of NSAIDs in both mediums (osteogenic and
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Table 1:Monoclonal antibodies (MABs) used to study the effect of dexketorpofen, ketorolac,metamizole, and acetylsalicylic acid on antigenic
phenotype of culturedMG63 osteoblastic-like cells, showing their specificity, and the fluorochrome used to label the antibody and the supplier.
MABs CD/specificity Fluorochrome Supplier
CONTROL — FITC Invitrogen Corp., (Carlsbad, CA, USA)
CD54/IOL1b CD54 FITC Invitrogen Corp., (Carlsbad, CA, USA)
CD80 CD80 FITC Invitrogen Corp., (Carlsbad, CA, USA)
CD86 CD86 FITC Invitrogen Corp., (Carlsbad, CA, USA)
OKDR HLA-DR FITC Invitrogen Corp., (Carlsbad, CA, USA)
FITC: fluorescein isothiocyanate.
nonosteogenic). After removing the supernatant, the samples
were washed gently with sterile PBS and were fixed with 3.7%
formalin for 30min. After that, dehydrated the cells through
a series of graded alcohols andwere allowed the samples to air
dry in a sterile flow hood. After 24 h, cells were coated with
palladium, and finally the samples were analyzed by SEM.
2.4.2. Alkaline Phosphatase Activity. ALP activity was quanti-
fied using a colorimetric assay (Diagnostic kit 104-LL, Sigma,
St. Louis, MO, USA) to determine early osteoblastic differen-
tiation. The assay measures the conversion of the colourless
substrate 𝑝-nitrophenylphosphate by the enzyme ALP to the
yellow product 𝑝-nitrophenol, with the rate of colour change
corresponding to the amount of enzyme present in solution.
Standards of 𝑝-nitrophenol (0–250𝜇M) were prepared from
dilutions of a 1000 𝜇M stock solution and assayed in parallel.
The ALP assay was performed as described by Sandrini et
al. (2005) [25]. The cells in osteogenic and nonosteogenic
mediums with NSAIDs or without drugs (control group)
were seeded at 1 × 104 cells/mL per well into 24-well plates
and cultured for seven days under standard conditions.Then,
cells were lysed with 0.1% (v/v) Triton X-100, at 37∘C. The
samples were centrifuged at 1500 rpm, and the supernatants
were stored at −70∘C until used. ALP activity was determined
with 50𝜇L of 𝑝-nitrophenylphosphate (Sigma, St. Louis,
MO, USA) as substrate and 50𝜇L of cells lysate solution
and was incubated at 37∘C for 45min in darkness. The
enzymatic reaction was stopped by adding 50 𝜇L of 0.1M
NaOH, and finally, the absorbance was measured at 405 nm
with a spectrophotometer (Biotek ELx800). The total protein
content was also estimated by a protein assay kit from Bio-
Rad Laboratories (Nazareth-Eke, Belgium), based on the
Bradford’s method. All samples were run in triplicate, and
specific ALP activity was expressed in U/mg cellular protein.
2.4.3. Matrix Mineralization. The presence of calcium depo-
sits into the cellular matrix was analysed by Alizarin Red
S. MG-63 cells were seeded (5 × 104 cells/mL/well) in a 6-
well plate and cultured in osteogenic medium with different
concentrations of NSAIDs assayed at 37∘C in a humidified
atmosphere of 95% air and 5% CO
2
. The medium was
replaced after 4 days and then every 3 days. We examined the
matrix mineralization of each cell line after 7, 15, and 22 days
of culture. Wells were washed with 150mM sodium chloride,
fixed in cold 70% ethanol for 5min, and rinsed three times
with distilled water. Wells were then incubated for 10min
with 1mL of 2% alizarin red S solution buffered at pH 4
with sodium hydroxide, then rinsed five times with distilled
water, and finally washed with PBS to reduce nonspecific
staining. Calcium deposits present in the extracellular colla-
gen matrix were coloured red, revealing the mineralization
nodules, which were counted under light microscopy. Images
of stained cultures were captured with a digital camera.
Results are expressed qualitatively based on the number of
red nodules observed per well, considering (−) = no nodules,
(+) = 5–20 nodules, and (++) => 20 nodules per well.
2.5. Cell Viability. Cell viability was assessed by counting
cells under fluorescent microscopy. Cells were cultured and
treated with the different drugs for 24 h. Hoechst/Propidium
Iodide (HPI) staining solution was prepared, mixing 20 L of
Hoechst 33342 solution (10 𝜇g/mL−1) with 20𝜇L propidium
iodide solution (10 𝜇g/mL−1) in 460𝜇L of culture media. The
media contained in the wells was removed, and samples were
washed three times with 1mL of sterile PBS by gently suck-
ing/pipetting action. Clean samples were then stained with
10 𝜇L of HPI staining.The number of alive and apoptotic cells
were scored by fluorescencemicroscopy at 40xmagnification;
six different fields per sample were counted. The data were
expressed as mean value.
2.6. Statistical Analysis. SPSS version 17.0 (SPSS, Chicago, IL)
was used for the data analysis. Mean values (±standard devi-
ation) were calculated for each variable. Analysis of variance
(ANOVA) was performed to examine the effects on ALP
synthesis considering treatment (dexketoprofen, ketorolac,
metamizole, or acetylsalicylic acid) and concentration (1 and
10 𝜇M) compared with control group. Antigenic profile and
phagocytic activity were compared using the Student’s 𝑡-test.
𝑃 < 0.05 was considered statistically significant in all tests.
At least three experiments were performed in all assays. Data
were expressed as mean ± standard deviation (SD).
3. Results and Discussion
3.1. Effect of NSAID on Antigenic Phenotype. The growth
of control MG63 in nonosteogenic medium provided an
antigenic profile typical of osteoblasts thus enabling a study
of NSAID effect at therapeutic doses that could reflect that
of primary osteoblasts. Indeed, flow cytometry showed
that 75% of the control MG63 population expressed CD54,
a cell adhesion protein highly expressed in osteoblast.
The osteoblast phenotypic pattern was completed by the
expression of CD80, CD86, and HLA-DR. These markers,
shared by osteoblasts and immunocompetent cells, were
all present in the cells albeit at a significantly lower levels.
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Table 2: Percentage of expression (by flow cytometry) of different antigens expressed in MG63 cell line after 24 h of treatment with different
anti-inflammatories, at doses of 1 and 10𝜇M.
Treatment
Monoclonal antibodies
CD54 CD80 CD86 HLA-DR
%, SDa 𝑃 %, SDa 𝑃 %, SDa 𝑃 %, SDa 𝑃
Control 75.5 (0.83) — 19.9 (0.83) — 13.1 (0.20) — 5.2 (0.26) —
Metamizole 1 𝜇M 97.7 (0.57) 0.00∗ 17.6 (0.61) 0.018∗ 10.1 (0.6) 0.001∗ 4.13 (0.49) 0.03∗
Metamizole 10𝜇M 97.3 (0.2) 0.00∗ 14.4 (1.24) 0.003∗ 8.8 (0.1) 0.00∗ 3.8 (0.36) 0.006∗
Dexketoprofen 1 𝜇M 97 (0.8) 0.00∗ 14.4 (1.24) 0.003∗ 9.7 (1.05) 0.005∗ 4.43 (0.75) 0.17
Dexketoprofen 10𝜇M 98.2 (0.15) 0.00∗ 17 (2.36) 0.11 11.2 (0.96) 0.06 5.56 (1.74) 0.73
Ketorolac 1 𝜇M 98.2 (0.17) 0.00∗ 16.3 (2.13) 0.11 13.43 (4.38) 0.926 5.76 (1.77) 0.63
Ketorolac 10𝜇M 97.6 (0.1) 0.00∗ 16.6 (2.13) 0.055 10.2 (0.45) 0.001∗ 4.73 (0.58) 0.27
Acetylsalicylic acid 1 𝜇M 98.1 (0.5) 0.00∗ 18.8 (2.45) 0.51 11.8 (1.37) 0.24 5.06 (0.35) 0.627
Acetylsalicylic acid 10 𝜇M 98.3 (0.36) 0.00∗ 18.8 (0.45) 0.12 11.2 (1.49) 0.09 5.26 (0.46) 0.839
aStandard deviation, ∗significant differences 𝑃 < 0.05.
Bold values is the statistical significance.
Table 3: Percentage of cells with phagocyte capacity determinate by
flow cytometry; treated with metamizole, dexketoprofen, ketorolac,
and acetylsalicylic acid at doses of 1 and 10 𝜇M.
Treatment % of cells phagocytes(mean value) SD
a
𝑃 value
Control 98.89 1.5217
Metamizole 1 𝜇M 78.20 1.9287 0.000∗
Metamizole 10𝜇M 65.10 11.8528 0.038∗
Dexketoprofen 1 𝜇M 90.39 2.3180 0.001∗
Dexketoprofen 10𝜇M 87.36 1.5534 0.001∗
Ketorolac 1 𝜇M 68.93 7.2037 0.017∗
Ketorolac 10𝜇M 62.96 5.9877 0.007∗
Acetylsalicylic Acid 1 𝜇M 96.29 1.7235 0.035
Acetylsalicylic Acid 10𝜇M 88.47 1.9612 0.000∗
aStandard deviation, ∗significant differences 𝑃 < 0.05.
NSAIDs stimuli at both 1 and 10𝜇M doses clearly altered
these patterns of expression. Treatment with metamizole,
dexketoprofen, ketorolac, and acetylsalicylic acid at 1 and
10 𝜇M doses for 24 h significantly increased the expression of
CD54 above 90% of the whole cell population (𝑃 < 0.001).
Flow cytometry results also showed that the modulation of
the expression of CD80, CD86, and HLA-DR by the tested
drugs depended on the type of NSAID used and their dosage.
The incubation with 1 and 10 𝜇M of metamizole for 24 h
significantly decreased the expression of CD80, CD86, and
HLA-DR (Figure 1(a) and Table 2). However, dexketoprofen
decreased the expression of CD80 and CD86 antigens only
at doses of 1𝜇M (𝑃 = 0.003 and 𝑃 = 0.005, resp.) (Figure 1(b)
and Table 2), and ketorolac decreased only the expression
of CD86 (𝑃 < 0.001) at higher concentration (Figure 1(c)
and Table 2). The treatment with acetylsalicylic acid at both
doses did not modify the expression of CD80, CD86, and
HLA-DR antigens (Figure 1(d) and Table 2).
3.2. Effect of NSAID on Phagocytic Activity. The overall
increase of markers of cell adhesion and reduced expression
markers shared by the osteoblasts with immunocompetent
Table 4: (a) ALP activity of MG63-line cell after 24 h of treatment
with different NSAIDs at doses of 1 y 10 𝜇M, in non-osteogenic
medium, expressed in U/mg of proteins. (b) ALP activity of MG63
line cell after 24 h treatment with different NSAIDs at doses of 1 y
10𝜇M, in osteogenic medium, expressed in U/mg of proteins.
(a)
Treatment Mean SDa 𝑃 value
Control 2.67 0.117
Dexketoprofen 1 𝜇M 1.77 0.253 0.005∗
Dexketoprofen 10𝜇M 1.88 0.207 0.005∗
Ketorolac 1 𝜇M 1.65 0.338 0.008∗
Ketorolac 10 𝜇M 1.79 0.184 0.002∗
Metamizole 1 𝜇M 1.69 0.030 0.000∗
Metamizole 10𝜇M 1.92 0.083 0.001∗
Acetylsalicylic acid 1 𝜇M 1.77 0.137 0.001∗
Acetylsalicylic acid 10 𝜇M 1.95 0.173 0.005∗
aStandard deviation, ∗significant differences 𝑃 < 0.05.
(b)
Treatment Mean SDa 𝑃 value
Control 2.37 0.092
Dexketoprofen 1 𝜇M 2.44 0.293 0.718
Dexketoprofen 10𝜇M 2.76 0.392 0.165
Ketorolac 1 𝜇M 2.68 1.772 0.029
Ketorolac 10 𝜇M 3.01 3.522 0.216
Metamizole 1 𝜇M 2.43 0.319 0.775
Metamizole 10𝜇M 3.70 1.602 0.223
Acetylsalicylic acid 1 𝜇M 2.54 1.878 0.446
Acetylsalicylic acid 10 𝜇M 3.31 0.478 0.602
aStandard deviation.
cells prompted the study of their phagocytic activity. Con-
sistently with the overall reduction of the immunocompe-
tent markers, NSAIDs significantly reduced the phagocytic
capacity of MG-63 cells, which was significantly decreased
after a 24 h treatment with 1 and 10 𝜇M of dexketoprofen,
ketorolac, and metamizole (𝑃 < 0.038). Only higher dosage
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Table 5: Qualitative study of mineralization of MG63 cell line through formation of nodules, in relation to time, cultured in osteogenic
medium supplemented with different NSAIDs: dexketoprofen, ketorolac, metamizole, and acetylsalicylic acid (1 and 10𝜇M).
Treatment 7 days 15 days 20 days
Number of nodules Size of nodules Number of nodules Size of nodules Number of nodules Size of nodules
Control − − + 40–80 𝜇m ++ 80–150 𝜇m
Acetylsalicylic acid 1 𝜇M − − ± 10–40𝜇m + 50–100 𝜇m
Acetylsalicylic acid 10 𝜇M − − ± 10–40𝜇m + 50–100 𝜇m
Dexketoprofen 1 𝜇M − − − − + 50–100 𝜇m
Dexketoprofen 10𝜇M − − − − − −
Ketorolac 1 𝜇M − − − − + 40–80𝜇m
Ketorolac 10𝜇M − − − − + 40–80𝜇m
Metamizole 1 𝜇M − − − − + 10–40 𝜇m
Metamizole 10𝜇M − − − − − −
− No detected nodules; ± of 0 to 10 nodules per well; + of 5 to 20 nodules per well; ++ more than 20 nodules per well.
acetylsalicylic acid led to a similar reduction of this specific
cellular activity (𝑃 < 0.001) (Figure 2 and Table 3).
3.3. Effect of NSAID on Early MG63 Differentiation. The
evidence of inhibition of the osteoblast immunocompetent
phenotype led to the investigation of the effect of the NSAIDs
on the ability of the cells to synthesise collagen, the main
component of the osteoid, the immature extracellular matrix
deposited during bone formation. This parameter of cell
synthetic activity was associated to those of matrix miner-
alization that were studied through the early ALP specific
activity and the later mineralized nodule formation.
3.3.1. Effect of NSAID on Collagen Synthesis. MG63 was
not affected in its early ability to synthesise collagen. The
qualitative analysis of collagen synthesis by MG-63 cells
cultured in nonosteogenic and osteogenic media after 24 h
incubation with the different drugs doses (1 and 10𝜇M)
(Figures 3 and 4) showed similar levels of positive staining
mainly confined within the cytoplasm. SEM analysis clearly
showed that the early synthesis of intracellular collagen fibrils
detected by Sirius red was followed by secretion into the
pericellular space after 7 days indicating a protected ability
of these cells to produce extracellular matrix following drugs
stimulation (Figures 5(a) and 5(b)).
3.3.2. Effect of NSAIDs on MG63 Specific ALP Activity. The
effect of the NSAIDs on the early biochemical pathway
leading to extracellular matrix mineralization was studied
by focusing on the assessment of the early levels of ALP
activity. ALP measurements were performed on MG-63 cells
cultured in osteogenic and nonosteogenic media, spiked
with 1 and 10 𝜇M of dexketoprofen, ketorolac, metamizole,
and acetylsalicylic acid. The results obtained are included in
Tables 4(a) and 4(b) showing a significant decrease in the
expression of this marker of differentiation when compared
to control cells in all drug spiking and in nonosteogenic
medium. However, when the experiment was performed in
osteogenicmedium a trend towards dose-dependent increase
of the ALP specific activity was observed; statistical analysis
was showing no significant difference.
3.3.3. Effect of NSAID on Matrix Mineralization. The effect
of the drug-reduced mineralization potential of the osteoid
by the osteoblast ALP activity was observed by the late
study of nodule mineralization. Table 5 exhibits data on
the number of red alizarin-stained mineralization nodules
counted under light microscopy after 7, 15, and 20 days of
culture in osteogenic medium. In control groups (untreated)
at 7 days of culture, no nodules were observed in any well;
at 15 days of culture, small nodules started to appear, and at
22 days of culture the number and size of nodules increased.
Cells treated with dexketoprofen, ketorolac, metamizole, and
acetylsalicylic acid (1 and 10 𝜇M) showed an inhibition in
both the number and the size of nodules as compared to
control group.
3.4. Effect of NSAID on MG63 Viability. MG63 viability was
significantly reduced by the differentNSAIDswhen the drugs
were tested at a 10 𝜇M dose in both nonosteogenic and
osteogenic media after 24 h incubation (Figures 6(a) and
6(b)). HPI staining clearly showed an increase in apoptotic
cells that were identified through the condensation of their
chromatin appearing as bright staining by epifluorescence
microscopy (Figure 6(c), arrows). The reduced cell viability
appeared to depend on both the type of drug tested and
the medium in which cells were cultured. When ketorolac
and dexketoprofen were added in a nonosteogenic medium a
significant increase of apoptotic cells was observed; metami-
zole and acetylsalicylic acid also increase the number of
apoptotic cells but not significantly. While in osteogenic
medium apoptosis was mainly stimulated ketorolac and
metamizole compared with the control. The staining also
showed a progression of the apoptotic process into necrosis;
the process was appearing to be relatively faster in osteogenic
medium (data not shown).
Osteoblasts are the most important cells in bone tis-
sue; they play an important role in the processes of bone
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Figure 1: Percentage of expression of different surfaces markers of the osteoblast (MG-63), treated for 24 h with doses of 1 and 10 𝜇M of (a)
metamizole, (b) dexketoprofen, (c) ketorolac, and (d) acetylsalicylic acid. ∗𝑃 < 0.01; ∗∗𝑃 = 0.001; 𝜑𝑃 = 0.003; #𝑃 = 0.005; †𝑃 = 0.006;
¥
𝑃 = 0.03; ‡𝑃 = 0.018.
remodeling and formation. The growth, antigenic profile,
and differentiation of osteoblasts are regulated by multiples
local and systemic factors, which may regulate activity of a
specific transcription factor [16, 26, 27]. These factors may
show different effect on modulation of cellular metabolism
depending on maturation and cell phenotype [28].
In this study, MG-63 cell line was used since they are rec-
ognized as cells the phenotype of which closely resembles that
of primary osteoblasts. Indeed, in 2009 Dı´az-Rodr´ıguez et al.
[22] described that this cell line has a similar antigenic prolife
to that described in primary cultured human osteoblasts as
in human bone tissue sections [21, 23]. The flow cytometry
characterization of the control cells confirmed these findings
validating the use of these cells for the study of the drug
effect. Although with various patterns and efficacy all the
tested drugs, but acetylsalicylic acid, appeared to inhibit the
expression of the testedmarkers of expression for an immune
phenotype and suggested an overall phenotypic pattern with
an enhanced ability to adhere to the extracellular matrix, but
as immature osteoblasts.
The antigen CD54 express in a high percentage of
MG63 cell line suffered a significant increase after 24 h of
treatment with different NSAIDs. However, a slight decrease
or no effect was observed in the expression of CD80,
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Figure 2: Fluorescence histogram of the phagocyte capacity of MG-63 cell line after treatment with different NSAIDs at doses of 1 and
10𝜇M in comparison to control, determined by means of flow cytometry. (a) Control; (b) dexketoprofen 1𝜇M; (c) dexketoprofen 10𝜇M; (d)
ketorolac 1 𝜇M; (e) ketorolac 10𝜇M; (f) metamizole 1 𝜇M; (g) metamizole 10 𝜇M; (h) acetylsalicylic acid 1 𝜇M; (i) acetylsalicylic acid 10 𝜇M.
These results are an example of one experiment.
8 The Scientific World Journal
(a4) (c4)(b4)
(a3) (c3)(b3)
(a2) (c2)(b2)
(a1) (c1)(b1)
Figure 3: Pictures were taken under optical microscopy of the cells treated for 24 h with different NSAIDs ((1) dexketorpofen; (2) ketorolac;
(3) metamizole; (4) acetylsalicylic acid) at different doses ((a) control; (b) 1 𝜇M; (c) 10𝜇M) in nonosteogenic medium and dyed with Sirius
red for to see the synthesis of collagen fibrins. Bars = 50𝜇m.
CD86, and HLA-DR. Acetylsalicylic acid showed no effect
on the percentage of expression of any markers assayed.
Dexketoprofen reduced CD80 and CD86 expression, and
ketorolac decreased the percentage of expression on CD86.
Only treatment with metamizole produced an inhibition of
the three markers CD80, CD86, and HLA-DR at the two
doses studied.
Preosteoblasts and inmature osteoblasts express highly
CD54 antigen [18], so its expression is related to the degree of
cell differentiation and maturation. However, this expression
can be modulated in presence of different biomolecules.
Thus, it is known that primary cultures of human osteoblasts
treatment with IL-1, IFN𝛾, or LPS increased the expression of
CD54 antigen [27].
Osteoblasts and dendritic cells have characteristics in
common including cytokine synthesis, phagocytic capacity,
antigenic presentation to T lymphocytes, and the expression
of certain antigens such as CD54, CD80, CD86, andHLA-DR
[16, 19, 29]. The expression of these markers has been related
to the degree of differentiation and/or cellular activation in
both populations. Like us, other authors have studied the
effect of acetylsalicylic acid on dendritic cells and found
that immature dendritic cells treated with acetylsalicylic acid
enhanced CD54 expression and decreased the expression
of costimulatory molecules expression. These authors con-
cluded that acetylsalicylic acid inhibits in vitro maturation
and in vivo immunostimulatory function ofmurine dendritic
cells [30, 31].
Dendritic cells are known to undergo two well-defined
maturation stages, comprising immature dendritic cells and
mature dendritic cells. Maturation of dendritic cells is asso-
ciated with an increase of costimulatory molecules and
with a more effective processing and presentation of anti-
gens [29]. Comparative analysis of the two populations,
osteoblasts and dendritic cells, suggests that the NSAIDs
studied can inhibit osteoblasts differentiation and matura-
tion.
The treatment of MG-63 cell line with a higher dose
(25 𝜇M) increased the expression of antigens CD21, CD44,
CD80, CD86, and HLA-DR but not CD54 expression and
decreased phagocytic activity [32]. However, this same
research group found that the effect on primary human
osteoblasts after treatment with ibuprofen did not change
antigenic profile and phagocytic capacity [33]. These differ-
ences are attributed to different degrees of maturation of the
osteoblasts in both studies.
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Figure 4: Pictures were taken under optical microscopy of the cells treated for 24 h with different NSAIDs ((1) dexketoprofen; (2) ketorolac;
(3) metamizole; (4) acetylsalicylic acid) at different doses ((a) control; (b) 1 𝜇M; (c) 10𝜇M) in osteogenic medium and dyed with Sirius red
for to see the synthesis of collagen fibrins. Bars = 50 𝜇m.
The osteoblasts are cells that have a phagocytic capacity
against different types and sizes of target particles [22]. The
results of the present paper show that the treatment with
dexketoprofen, ketorolac, metamizole, and acetylsalicylic
acid decreases the phagocytic capacity of MG63 cell line in
a dose-dependent manner. This effect would not be related
to the behavior of dendritic cells because this phagocytic
capacity decreases with maturation [29]. However, this is an
effect commonly observed when the MG63 cell line has been
treated with different NSAIDs [32, 34].
The treatment of MG-63 osteoblastic cells with dexke-
toprofen, ketorolac, metamizole, and acetylsalicylic acid, at
therapeutic doses, led to no short-term effect on the ability of
the cells to synthesise and deposit nonmineralized immature
osteoid.
However, the biomineralization of the deposited colla-
genic extracellular matrix appeared to be inhibited unless
osteogenic stimuli were provided to the cells. Osteoblasts
differentiation and maturation evolve through a complex
process regulated by multiple exogenous factors includ-
ing growth factors, mechanical stimuli, or pharmacological
treatments [31, 35–39]. Among the latter, works have been
dedicated to unveiling the effect of various anti-inflammatory
drugs. In particular, Abukawa and colleagues (2009) [39]
found that high doses of ibuprofen (1 y 3mmol/L) had a
negative effect on differentiation of porcine osteoblastic cells
finding suppression of ALP activity and decrease of miner-
alization matrix production. Also, short-term treatment with
therapeutic doses of acetaminophen reduces cell proliferation
and osteocalcin synthesis [34].
The inhibitory effect of NSAIDs on bone remodeling is
also corroborated by the effect of the tested drugs on cell via-
bility. The treatment of the MG-63 osteoblast-like cells with
the various NSAIDs showed an increase in the percentage of
apoptotic osteoblasts lately developing into necrotic cells. It
can be speculated that this reduced cell viability would alter
remodeling with osteoblasts experiencing a reduced viability
and ability to mineralize the deposited extracellular matrix.
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Figure 5: SEM: Effect of NSAIDs on collagen synthesis; cells were incubated in nonosteogenic and osteogenic mediums and treated at a dose
of 10𝜇M, for 7 days.
4. Conclusions
Thepresent studies have applied an in vitro cell culturemodel
based on osteosarcoma MG-63 osteoblast-like cells to study
the effect of therapeutic concentrations of several types of
NSAIDs.The choice ofmarkers of expression and phenotypic
differentiation at short and prolonged time of exposure of
the cells to the drugs has allowed to unveil that, although
with differences, this class of anti-inflammatory substances
can alter bone remodeling by reducing cell maturation, its
longevity and biochemical machinery necessary to miner-
alize the deposited extracellular matrix. It may therefore be
speculated that their protracted use could indeed lead to
pathological conditions such as osteoporosis.
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